Chengda Pharmaceutical Co., Ltd.

Announcement of the 2025 Annual Shareholders' Meeting Resolution

Witness Legal Opinion from Guohao Law Firm (Shanghai) on the 2025 Annual Shareholders' Meeting of Chengda Pharmaceutical Co., Ltd.

Everbright Securities Co., Ltd. 2025 Annual Tracking Report for Chengda Pharmaceutical Co., Ltd.

Everbright Securities Co., Ltd. Summary Report on Continuous Supervision and Sponsorship for Chengda Pharmaceutical Co., Ltd.'s Initial Public Offering and Listing on the Growth Enterprise Market

Announcement on holding the 2025 annual performance briefing

Pre-Disclosure Announcement on the Share Reduction by Shareholders Holding More Than 5%

Announcement on the Reappointment of Accounting Firm

Announcement on the Compensation Plan for Directors and Senior Management for 2026

2025 Board of Directors Work Report

Announcement on Adjusting the Company's Organizational Structure

2025 Independent Director Work Report (Cui Sunliang)

2025 Independent Director Work Report (Jiang Lin)

2025 Independent Director Work Report (Wang Ping)

2025 Independent Director Work Report (Yu Yi)

2025 Independent Director Work Report (Zhou Junming)

2025 Independent Director Work Report (Hu Yongzhou)

Everbright Securities Co., Ltd. Verification Opinion on Chengda Pharmaceutical Co., Ltd. 2025 Internal Control Evaluation Report

Chengda Pharmaceutical Co., Ltd. 2025 Internal Control Audit Report

2025 Internal Control Evaluation Report

Compensation Management System for Directors and Senior Management

Announcement on the Provision for Asset Impairment for the Year 2025

Announcement on the Provision for Asset Impairment for Q1 2026

Announcement on the Company's and Subsidiaries' Application for Comprehensive Credit Limits from Banks for 2026

Notice of the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the Fourth Meeting of the Sixth Board of Directors

Announcement on the Profit Distribution Plan for the Year 2025

2026 Q1 Report

2025 Annual Special Report on the Storage, Management, and Use of Raised Funds

Chengda Pharmaceutical Co., Ltd. 2025 Annual Verification Report on the Storage, Management, and Use of Raised Funds

Everbright Securities Co., Ltd. Special Verification Report on Chengda Pharmaceutical Co., Ltd. 2025 Annual Storage, Management, and Use of Raised Funds

Chengda Pharmaceutical Co., Ltd. 2025 Annual Special Audit Report on Operating Income Deductions

Report on the Evaluation of the Accounting Firm's Performance in 2025 and the Audit Committee's Fulfillment of Supervisory Responsibilities

Chengda Pharmaceutical Co., Ltd. 2025 Annual Special Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions

2025 Annual Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Board of Directors Special Opinion on the Independence Self-Examination of Independent Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Announcement on abnormal fluctuations in stock trading